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and age-related diseases. Growing evidence suggests that
autophagy is implicated in cell injury during renal diseases,
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glomeruli. Nevertheless, the impact of autophagy on renal
disease progression and aging is still not fully understood.
This review summarizes the recent advances in
understanding the role of autophagy for kidney disease
and aging.
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950A utophagy (“self-eating” in Greek) is a highly regulatedlysosomal protein degradation pathway that removesprotein aggregates and damaged organelles to main-
tain intracellular homeostasis and cell integrity.1–3 This pro-
cess was ﬁrst described in 1957 by Sam Clark Jr.,4 but the
term autophagy was coined by Christian de Duve only in
the late 1950s.5 The autophagy process is well conserved in
the evolution from yeast to mammals.6,7 Characterization
of the molecular regulators of autophagy was ﬁrst described
in the 1990s with the identiﬁcation of autophagy-related
genes (ATGs) in autophagy-defective yeast cells,8,9 Then
mammal orthologs and the molecular machinery were
identiﬁed.10
Three types of autophagy have been described to date as
follows: macroautophagy, the most studied form and the
focus of this review; microautophagy; and chaperone-
mediated autophagy. All differ in their mechanisms and
functions11: microautophagy involves the engulfment of small
cytoplasmic cargos within lysosomal membrane in-
vaginations12 and chaperone-mediated autophagy involves
the heat shock cognate protein 70–mediated recruitment of
KFERQ motif–bearing proteins to the lysosome,13,14 whereas
macroautophagy is the most prevalent and probably less se-
lective type and is referred to in this review as autophagy.
In this review, we describe the pathway of autophagy and
highlight its role in renal physiology, renal aging, and kidney
diseases. We will also discuss the potential implication of
manipulating autophagy as a potential novel renoprotective
therapeutic strategy.AUTOPHAGY
Functions of autophagy
Autophagy has been demonstrated to be essential for a
number of fundamental biological activities,15 such as the
maintenance of cellular homeostasis and cellular stress
response, particularly in postmitotic cells. Autophagy partic-
ipates in recycling of organelles such as mitochondria
(mitophagy),16,17 endoplasmic reticulum (ER), and peroxi-
somes7,18–22; the clearance of polyubiquitinated proteins ag-
gregates23; and lipid degradation (lipophagy).24 Dysregulation
of autophagy is involved in the pathogenesis of a variety of
metabolic and age-related diseases.25–31 The major role ofKidney International (2016) 90, 950–964
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stress conditions and to serve as a quality control by clearing
misfolded proteins and others cellular debris. Interestingly,
genetic evidence (i.e., polymorphisms in ATGs) indicates that
autophagy is implicated in several immune diseases associated
with kidney dysfunction, such as systemic lupus erythema-
tosus (autophagy related 5 gene [ATG5])32 and rheumatoid
arthritis (the PR domain 1 gene [PRDM1]-ATG5 intergenic
region).33 Furthermore, activation of autophagy at the whole-
body level extends the life span of various model organisms,
including mice.28 There is a growing amount of evidence that
dysregulation of the autophagic pathway is implicated in the
pathogenesis of kidney aging and in several renal diseases
such as acute kidney injury (AKI), polycystic kidney disease
(PKD), diabetic nephropathy (DN), obstructive nephropathy,
focal and segmental glomerulosclerosis (FSGS), and poten-
tially other kidney diseases.34–37
Molecular mechanisms of autophagy
Autophagy proceeds through at least ﬁve steps. Autophago-
somes are initiated by expansion and sealing of a small vesicle
made of a double-membrane structure called phagophore
or isolation membrane. The origin of the autophagosomeFigure 1 | Autophagy pathway. The autophagic pathway responds to
through the mTOR signaling pathway. The class I PI3K-AKT can also act
factors, acting as a negative regulator of autophagy. Activation of AMPK
(ii) activates the ULK1 complex through ULK1 and ATG13 phosphorylatio
energy depletion. The BECN1/class III PI3K complex, which is inactivated
Upon activation, the Beclin1-VPS34-ATG14L-P150 complex will generate
coordination with the ULK1-ATG13-ATG101-FIP200 complex. The ATG5-AT
will play roles in cargo recruitment, membrane elongation, and autopha
autolysosome is mediated through SNARE proteins, and lysosomal hydr
B; AMPK, adenosine monophosphate–activated protein kinase; ATG, aut
lymphoma–extra large; DEPTOR, DEP domain-containing mTOR-interacti
LC3, microtubule-associated protein 1 light chain 3; MLST8, target of rapa
mTORC1, mTOR complex 1; PI3K, phosphatidylinositol-3-kinase; PI3P, ph
thymoma viral oncogene homolog 1 substrate 40 kDa; Raptor, regulatory
receptor; ULK1, Unc51-like kinase 1.
Kidney International (2016) 90, 950–964membrane may involve different sources, such as lipid
droplets, mitochondria, Golgi, ER, plasma membrane, and
recycling endosomes.38,39 The phagophore is generated at a
specialized site known as the phagophore assembly site or
preautophagosomal structure. Sixteen ATG proteins comprise
the conserved core ATG machinery that catalyzes formation
of the phagophore and its expansion into autophagosomes in
all eukaryotes40 (Figure 1). The metabolites generated in the
lysosomes/vacuoles are subsequently transported in the
cytoplasm and recycled. Macroautophagy has recently been
shown to achieve some selectivity for lipid droplets, ribo-
somes, pathogens, surplus reticulum, peroxisomes, enzymes,
and proteins aggregates in processes that are called lipophagy,
ribophagy, xenophagy, reticulophagy, pexophagy, zymophagy,
and aggrephagy, respectively (reviewed and discussed in Bir-
gisdottir et al.,41 Johansen and Lamark,42 Johansen and
Lamark,43 Mochida et al.,44 Khaminets et al.,45 and Khami-
nets et al.46).
Selectivity of autophagy is controlled by autophagy
receptors that physically associate with the autophagy
compartment by interacting simultaneously with cargo and
Atg8- or microtubule-associated protein 1A/1B–light chain 3
(LC3)/g-aminobutyric acid receptor–associated protein–likesignals from the environment. Nutrients status controls autophagy
ivate the mTORC1 complex in response to insulin and other growth
in response to low energy status (i) inhibits the mTORC1 complex and
n, thereby acting as a positive regulator of autophagy in response to
by Bcl2, and the class I PI3K-AKT complex also regulate autophagy.
PI3P, which promotes autophagosomal membrane nucleation in
G12-ATG16L complex and the LC3-phosphatidylethanolamine system
gosome maturation. Lysosome fusion to autophagosome to form
olases degrade proteins, lipids, and nucleic acids. AKT, protein kinase
ophagy-related gene; BCL2, B-cell lymphoma 2; BCLXL, B-cell
ng protein; FIP200, FAK family kinase-interacting protein of 200 kDa;
mycin complex subunit LST8; mTOR, mammalian target of rapamycin;
osphatidylinositol-3-phosphate; PRAS40, proline-rich v-akt murine
-associated protein of mTOR; SNARE, soluble NSF attachment protein
951
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receptors are probably sequestosome 1 (SQSTM1)/p62 and
neighbor of breast cancer 1 gene (BRCA1) 1, which can
sequester aggregated proteins and form the SQSTM1/p62
bodies. One of the prevailing mechanisms to regulate and
often stimulate selective autophagy pathways includes phos-
phorylation of both cargo signals and autophagy receptors.
For example, the phosphate and tensin homolog–induced
putative kinase protein 1 and ubiquitin (UB) ligase Parkin act
cooperatively in sensing mitochondrial functional state and
directing damaged mitochondria for disposal via the auto-
phagy pathway (mitophagy). Putative kinase protein 1
phosphorylates UB to activate the UB ligase Parkin, which
builds UB chains on mitochondrial outer membrane proteins,
where they act to recruit autophagy receptors such as NDP52
and optineurin.48,49 The fast-evolving ﬁeld of UB-dependent
and independent signals in selective autophagy has been
reviewed recently.46
Monitoring autophagy
The accumulation of autophagosomes can be used to monitor
autophagy. It is important to keep in mind that accumulation
of autophagosomes can be caused by an increased autophagic
ﬂux or can be due to the inhibition of autophagosome-
lysosome fusion or inhibition of lysosomal enzyme func-
tion.50,51 The formation and maturation of autophagosomes
depends on several genes, including microtubule-associated
protein 1 light chain 3 (MAP1LC3A/B), beclin 1 gene
(BECN1), and ATGs.1,26,52,53 Microtubule-associated protein
1 light chain 3A/B is a soluble protein that belongs to the UB-
related system. The cytoplasmic LC3 is conjugated to phos-
phatidylethanolamine to produce LC3–PE (or LC3-II), which
is subsequently incorporated into to the double-membrane
structure of the autophagosome. Therefore, detecting the
intracellular level of LC3-II and conversion of cytoplasmic
LC3 into LC3-II by immunoﬂuorescence and Western blot
analysis can be used as marker for autophagy. However,
accumulation of LC3-positive vacuoles or LC3II protein could
be due to impaired autophagosome maturation or an accel-
eration of autophagic ﬂux, which can be further differentiated
by inhibition of autolysosomal degradation with baﬁlomycin
A1 or chloroquine. Additionally, the lysosomal turnover
of p62, which interacts with LC3-II, can also be used to
monitor the autophagic ﬂux.54 The use of an monomeric red
ﬂuorescent protein–green ﬂuorescent protein tandem
ﬂuorescent-tagged LC3 has also been proposed for visualizing
the autophagic ﬂux.55 We refer readers to landmark articles
and methodological guidelines.50,51,56,57
Regulation of autophagy
Autophagy is regulated by the major nutrient-sensing path-
ways, including the mammalian target of rapamycin com-
plex 1 (mTORC1), adenosine monophosphate–activated
protein kinase (AMPK), and oxidized nicotinamide adenine
dinucleotide–dependent histone deacetylase (sirtuin 1
[SIRT1]).1,58–62 The most powerful autophagy inducer is952starvation by induction of low levels of amino acids, glucose,
adenosine triphosphate, and growth factors. The activated
unc-51 like autophagy activating kinase 1 (ULK1) complex
(ULK1-ATG13-ATG101–FAK family kinase-interacting pro-
tein of 200 kDa) is recruited to the ER,52 where it activates
the class III phosphoinositide 3–kinase complex (beclin
1 [BECN1]-ATG14L-Vps34-p150) by phosphorylating
BECN1.63 The complex generates phosphatidylinositol 3–
phosphate, which recruits effectors to initiate autophagosome
formation.64,65 The lipid kinase activity of this phosphoino-
sitide 3–kinase complex I is enhanced upon dimerization
provoked by nuclear receptor binding factor 2 binding to
Atg14L.66 Membrane elongation, autophagosome maturation,
and cargo recruitment depend on two conjugation complexes:
the ATG5-ATG12-ATG16L1 complex and the LC3-
phosphatidylethanolamine complex.40 LC3 and SQSTM1
have primordial roles in cargo selection. LC3 is also essential
for autophagosomal membrane closure.67
Nutrition-related regulation of autophagy. Most of the
studies on autophagy regulation focus on the role of
mTORC1 complex. Mammalian target of rapamycin (mTOR)
is a serine/threonine protein kinase whose activity is associ-
ated with nutrient levels and redox status. The function of
TORC1 as a repressor of autophagy is conserved in mammals
and mTORC1 inhibits autophagy in many mammalian cell
types.68 It has been shown that mTORC1 interacts with the
ULK1 complex and inhibits autophagy induction through
phosphorylation of ULK1 and ATG13. Upon starvation,
inhibitory phosphorylation of the serine/threonine-protein
kinase ULK1 at Ser757 is removed, thereby allowing auto-
phagy induction.58,62,69 The functions of mTORC1 in
glomerular physiology have been well documented.70–72
In situations of low energy, cellular adenosine mono-
phosphate levels rise, leading to the activation of AMPK.73
AMPK is ubiquitously expressed and plays a major role in
cellular energy homeostasis by sensing levels of intracellular
calcium and adenosine triphosphate/adenosine mono-
phosphate ratio. AMPK is strongly expressed in several renal
cells including podocytes, mesangial cells, glomerular endo-
thelial cells and tubular cells. AMPK is activated through
phosphorylation on Ser72 by the calcium calmodulin-
dependent protein kinase kinase and the tumor suppressor
protein serine/threonine kinase 11.74,75 AMPK is an auto-
phagy inducer by phosphorylating ULK1 on Ser317 and
Ser777.62 Once activated, AMPK phosphorylates tuberous
sclerosis complex 2,76 which forms a complex with tuberous
sclerosis complex 1 protein, which acts as a guanosine
triphosphatase–activating protein toward Ras homolog
enriched in brain.77–79 Additionally, tuberous sclerosis com-
plex 2 phosphorylation by AMPK is a primer for further
phosphorylation by glycogen synthase kinase 3 beta, which
leads to Ras homolog enriched in brain–dependent inhibition
of mTORC1.80 AMPK was also shown to directly phosphor-
ylate raptor.81 However, the relative contribution of raptor
phosphorylation to overall mTORC1 regulation by AMPK
and the context in which raptor is implicated in mTORC1Kidney International (2016) 90, 950–964
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phagy and AMPK regulation in kidney cells is only incom-
pletely understood.34
The oxidized nicotinamide adenine dinucleotide–depen-
dent histone deacetylase (SIRT1) also regulates autophagy
through different targets and effectors.82,83 Sirtuins are a
family of histone and nonhistone deacetylases that are regu-
lated by nicotinamide adenine dinucleotide as a cofactor
linking their activity to the metabolic status of the cell.84
SIRT1 has been demonstrated to be an inducer of auto-
phagy by directly and indirectly acting on components of the
autophagy machinery. SIRT1 coimmunoprecipitates with
ATG5, ATG7, and ATG8/LC3 and can deacetylate these pro-
teins in a nicotinamide adenine dinucleotide–dependent
manner in vitro.61 Through deacetylation of transcription
factors that in turn activate autophagy genes, SIRT1 can also
indirectly modulate autophagy. This is the case for members
of the forkhead box O family.85,86 Interestingly, SIRT1-
mediated forkhead box O1 activation was shown to increase
expression of Rab7, a small guanosine triphosphatase that
mediates late autophagosome-lysosome fusion. Furthermore,
forkhead box O3 deacetylation by SIRT1 can upregulate
multiple autophagy-related genes such as unc-51 like auto-
phagy activating kinase 2 gene (ULK2), BECN1, phosphati-
dylinositol 3–kinase catalytic subunit type 3 gene (VPS34),
B-cell lymphoma 2 (BCL2)/adenovirus E1B 19kDa interact-
ing protein 3 gene (Bnip3) and BCL2/adenovirus E1B 19kDa
interacting protein 3 gene-like (Bnip3L), autophagy related 12
gene (Atg12), autophagy related 4B gene (Atg4B), LC3, and g-
aminobutyric acid receptor gene (GABAR)–amino acid per-
mase like gene (APL1).87 Recent evidence demonstrated
SIRT1 involvement in renal pathophysiology88–93 and the
aging kidney (see later).
Stress-induced regulation of autophagy (oxidative stress, ER
stress, hypoxia). In addition to nutrient starvation, intracel-
lular stress effectors can also modulate autophagy levels. Most
of the following evidence has been collected from nonrenal
cellular models. For example, reactive oxygen species can
inﬂuence LC3 production through activation of c-Jun N-
terminal protein kinase 194 and activation of protein kinase
RNA-like endoplasmic reticulum kinase.95
In the absence of clearly deciphered interaction between
ER stress and autophagy in the kidney, we will refer to a
recent review of the literature demonstrating that ER stress
serves dual roles by favoring both induction and inhibition of
autophagy.96
Modulation by hypoxia: interplay with oxidative stress and
proapoptotic and metabolic pathways. Evidence has accu-
mulated that hypoxia plays a signiﬁcant role in the patho-
genesis and progression of chronic renal disease.97
Depending on the severity and duration of the variations
in oxygen tension, hypoxia has been demonstrated to regulate
autophagy pathways differently. For instance, chronic and
moderate hypoxia induces autophagy through hypoxia-
inducible factor-1 alpha and PKCd–c-Jun N-terminal pro-
tein kinase 1–implicated pathways.98 Conversely, rapid andKidney International (2016) 90, 950–964severe oxygen ﬂuctuation could induce autophagy via
hypoxia-inducible factor–independent pathways.
Hypoxia can also activate autophagy through induction of
BCL2/adenovirus E15 19kDa interacting protein 3 (BNIP3),99
which can disrupt the inhibitory interaction between BECN1
and BCL2.100,98,101–103 Under conditions of hypoxia, BNIP3
transcription triggers mitochondrial dysfunction, formation
of autophagosomes, and promotion of the apoptosis process
in neonatal cardiac myocytes.104
By causing mitochondrial dysfunction, BNIP3 or BCL2/
adenovirus E1B 19kDa interacting protein 3-like may increase
production of reactive oxygen species, which can activate
autophagy.105 Competition by BNIP3 or BCL2/adenovirus
E1B 19kDa interacting protein 3-like for binding to BCL2 (or
a related protein) could also liberate BECN1 from BCL2
complexes and activate autophagy.106 In fact, this interplay
between proapoptotic pathways and proautophagy pathways
may lead to misinterpretation of the role of autophagy. For
example, overexpression of Bcl2 homolgy domain 3–only
proteins at some stages of kidney diseases may increase
autophagy by freeing BECN1 from BCL2, but the net result
may still be proapoptotic.107,108 Finally, BNIP3 binds to and
inhibits Ras homolog enriched in brain,109 which is an up-
stream activator of mTOR. Therefore, BNIP3 may activate
autophagy by repressing mTOR. Oxygen is also an essential
regulator of cellular metabolism affecting protein translation,
autophagy, and cell growth through mTOR regulation. In
response to hypoxia, regulation of mTORC1 occurs through a
conserved pathway that is independent of energy signaling
pathways.110,111 Under conditions of oxygen deprivation,
mTORC1 dissociates from the ULK1 to phosphorylate
ATG13/FAK family kinase-interacting protein of 200 kDa
complex and, thus, initiates autophagy in cells.79 Regulation
of mTORC1 and autophagy by hypoxia, however, seems to be
highly cell type–dependent and context dependent. Another
level of chronic hypoxia-dependent regulation is activation of
tuberous sclerosis complex 2 protein by the reduction of
adenosine triphosphate depletion and upregulation of AMPK
phosphorylation.112
Overall, both laboratory evidence and clinical evidence
highlight hypoxia as an important inducer of autophagy.
Future studies will have to elucidate whether the steep oxygen
gradient in the kidney is a physiological modulator of
autophagy.
AUTOPHAGY IN AGING AND DISEASED KIDNEYS
To date, the roles of autophagy in the diseased kidney have
been studied mainly in proximal tubular cells and podocytes.
The availability of mouse models genetically targeting the
autophagy machinery has facilitated our understanding of the
role of autophagy in kidney physiology and pathology
(Tables 1, 2, and 3).
Autophagy in glomerular aging and diseases
Podocytes have been identiﬁed as the most fragile cell types of
the glomerulus, and a decrease in the number of podocytes953
Table 1 | Effects on kidneys of global genetic targeting of autophagy genes
Name Tissue
Renal
disease
model Phenotype/renal phenotype Comments References
Atg3/, Atg5/,
Atg7/, Atg9/,
Atg16L1/
Global N/A Neonatal lethal No kidney abnormalities in Atg5-/- pups 113–117
Beclin1/ Global N/A Early embryonic lethal (E7.5) with defects in
proamniotic canal closure
118, 119
FIP200/ Global N/A Embryonic lethal (E13.5–E16.5) because of
defective heart and liver development
120
Ambra1gt/gt Global N/A Embryonic lethal (wE14) with defects in
neural tube development
121
Ulk1/ Global None Viable. Increased reticulocyte number with
delayed mitochondrial clearance
Kidney not studied 122
Atg4C/ Global None Viable. Increased tumorigenesis Kidney not studied 123
Map1lc3/ Global None None Normal renal histology in young adults 124
Gabarap/ Global None None Gabarap(-/-) mice have reduced urinary excretion of
P(i), higher Na(þ)-dependent (32)P(i) uptake in BBM
vesicles, and increased expression of NaPi-IIa in
renal BBM compared with Gabarap(þ/þ) mice. The
expression of Na(þ)/H(þ) exchanger regulatory
factor 1, an important scaffold for the apical
expression of NaPi-IIa, is also increased in
Gabarap(-/-) mice
125, 126
Sirt1þ/- Global UUO Increased oxidative stress, apoptosis and
ﬁbrosis after UUO
Lower autophagy activity and decreased BNIP3
expression
88
Map1lc3-GFP Global None None Demonstrate high level of autophagy in podocytes at
basal state
56, 141
IRI None Demonstrate that autophagic activity in the tubule
system is low at basal state and increased after IRI
192
CAG-RFP-EGFP-Map1lc3 Global IRI None Demonstrate that autophagic activity in the proximal
tubule system is increased after IRI
127
Atg3, autophagy related 3 gene; Atg4C, autophagy related 4C gene; Atg5, autophagy related 5 gene; Atg7, autophagy related 7 gene; Atg9, autophagy related 9 gene; Atg16L1,
autophagy related 16-like 1 gene; BBM, brush border membrane; EGFP, enhanced green ﬂuorescent protein; FIP200, FAK family kinase-interacting protein of 200 kDa gene;
GABARAP, g-aminobutyric acid receptor–associated pro; GFP, green ﬂuorescent protein; IRI, ischemia-reperfusion injury; LC3, microtubule-associated protein 1A/1B–light chain
3 gene; LC3B, microtubule-associated protein 1A/1B–light chain 3B gene; N/A, not applicable; RFP, red ﬂuorescent protein; SIRT1, sirtuin 1 gene; ULK1, unc-51 like autophagy
activating kinase 1; UUO, unilateral ureteral obstruction.
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progression in several renal diseases, such as DN, IgA ne-
phropathy, HIV-associated nephropathies, or FSGS.132–134
Glomerular endothelial cells are also altered in several renal
diseases (i.e., primary hypertension, DN, and other chronic
kidney diseases). Mechanisms of podocyte and glomerular
endothelial cell injuries are incompletely understood, but ER
stress, mitochondrial damage, and oxidative stress are impli-
cated in most types of glomerulosclerosis.135–138
Autophagy and glomerular maintenance during aging. Aging
induces the accumulation of damaged organelles and mito-
chondria as well as protein aggregates that are physiological
causes of organ dysfunction. The kidney is particularly sus-
ceptible to age-related renal damage such as tubular atrophy,
interstitial ﬁbrosis, and glomerulosclerosis. Elderly individuals
are particularly sensitive to ischemia and toxic stress and show
high rates of end-stage renal disease and chronic kidney
disease.139,140 In glomeruli, podocytes are terminally differen-
tiated postmitotic cells. Therefore, their capacities for regener-
ation are limited and they require efﬁcient cellular mechanisms
to “clean” themselves from protein aggregates and altered
organelles that will accumulate throughout a lifetime. Recent
evidence suggests that autophagy might be this cleaning
mechanism allowing podocyte maintenance during aging.954Unlike other renal and nonrenal cell types, podocytes have
a high level of basal autophagy, suggesting that autophagy
has important functions in this cell type.56,141 Further-
more, podocyte-speciﬁc deletion of Atg5 results in proteinuria,
loss of podocytes, and aging-related glomerulosclerosis,
thus demonstrating the primordial function of autophagy
for podocyte maintenance.141 Importantly, Atg5 knockout
podocytes showed the following typical age-related alteration:
lipofuscin accumulation, an increase in oxidized proteins, and
UB-positive and SQSTM1-positive protein aggregates.141
Concomitant with such results, podocyte-speciﬁc Vps34 dele-
tion leads to spontaneous development of glomerulosclerosis,
although defective autophagy was not primarily responsible
for the severe phenotype observed in Vps34-deﬁcient
podocytes.142–144 Finally, pharmacological inhibition of auto-
phagy induces podocyte apoptosis by activating the apoptotic
pathway of ER stress.145
Autophagy in FSGS. FSGS is a glomerular disease associ-
ated with podocytopathy that is associated with a poor
prognosis and evolves easily into end-stage renal disease.146
Several pieces of evidence suggest that autophagy is impli-
cated in podocytopathy during FSGS.141,147–150 In an initial
study it was demonstrated that podocyte-speciﬁc deﬁciency of
Atg5 (Nphs2.Cre Atg5lox/lox mice) sensitizes mice for theKidney International (2016) 90, 950–964
Table 2 | Effects of kidney cell–speciﬁc deletion of autophagy genes
Name Tissue
Cre-driven
expression Renal disease model Phenotype/renal phenotype Comments References
Nphs2-cre Atg5ﬂ/ﬂ Podocyte Nphs2 None Age-dependent late-onset
glomerulosclerosis.
Podocytes loss associated with
ubiquinated
protein aggregates.
141
LPS-, PAN-, doxorubicin-
(Adriamycin-), and
bortezomib-induced
proteinuria
Increased sensitivity to the development
of proteinuria
141
STZ-induced DN Increased sensitivity to the development
of podocyte
injury and apoptosis
167
HFD-induced proteinuria HFD-fed podo-Atg5/ mice develop
albuminuria with severe podocyte injury
178
Nphs2-cre Vps34ﬂ/ﬂ Podocyte Nphs2 None Massive proteinuria and early lethality.
Podocyte degeneration and early-onset
glomerulosclerosis
Abrogated
autophagic
ﬂux is not
causative of
the podocyte
phenotype
142, 144
Cdh5-cre Atg5ﬂ/ﬂ Endothelial Cdh5 STZ-induced DN Increased sensitivity to the development
of DN
167
Six2-cre Atg5ﬂ/ﬂ Podocytes, PEC,
tubules
Six2 None Tubulointerstitial damage and FSGS by 4
mo.
Lethality by 5 mo
150
Six2-cre Atg7ﬂ/ﬂ Podocytes, PEC,
tubules
Six2 None FSGS by 4 mo with moderate
albuminuria.
Less tubular injury than for the Six2-cre
Atg5ﬂ/ﬂ mice.
Survive until 1 yr
150
KAP-cre Atg5ﬂ/ﬂ Proximal tubule KAP Cisplatin and IRI Increased sensitivity to AKI 202, 230
FFA-albumin overload Increased sensitivity to the development
of tubular lesions
162
PEPCK-cre Atg7ﬂ/ﬂ Proximal tubule PEPCK Cisplatin and IRI Increased sensitivity to AKI 201
Pax8.rtTA;tetO.Cre
Atg5ﬂ/ﬂ
Proximal, distal
tubules l
and collecting duct
Pax8 None Few aberrant ultrastructure in tubular
cells 5 mo
after autophagy blockade
192
IRI Severe tubular injury. P62 and oxidative
injury markers accumulation
192
Ksp-cre Atg5ﬂ/ﬂ Distal tubule Ksp None Normal renal function. P62 accumulation
and increased oxidative stress markers
192
AKI, acute kidney injury; Atg5, autophagy related 5 gene; Cdh5, cadherin 5 gene; DN, diabetic nephropathy; FFA, free fatty acid; FSGS, focal and segmental glomerulosclerosis;
HFD, high-fat diet; IRI, ischemia-reperfusion injury; KAP, kidney androgen regulated protein gene; Ksp, cadherin 16, KSP-cadherin gene; LPS, lipopolysaccharide; Nphs2,
nephrosis 2, idiopathic, steroid-resistant (Podocin) gene; PAN, puromycin aminonucleoside nephrosis; Pax8, paired box 8 gene; PEPCK, phosphoenolpyruvate carboxykinase 2,
mitochondrial gene; Six2, SIX2 homeobox 2 gene; STZ, streptozotocin; Vps34, phosphatidylinositol 3– kinase gene.
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general theme of podocyte biology and glomerular disease.141
Podocyte injury was characterized by ER stress, accumulation
of oxidized proteins, and altered mitochondria.141 These re-
sults could also be conﬁrmed using Six2.Cre Atg5lox/lox mice
or Six2.Cre Atg7lox/lox mice.150 The more dramatic phenotype
caused by deletion of autophagy throughout the nephron
than that reported in models of autophagy deletion in tubular
or podocyte compartments solely unravels a strong effect of
autophagy on nephron development or integration of physi-
ological cross talk between the distinct parts of the nephron.
Autophagy was also found to have protective properties in
puromycin-aminonucleoside–treated human podocytes.151 A
decreased number of autophagic vacuoles was described in
podocytes from patients with FSGS.149 Finally, pharmaco-
logical induction of autophagy delays the progression ofKidney International (2016) 90, 950–964FSGS. Indeed, Wu et al. found that rapamycin could reduce
podocyte injury by inducing autophagy.152 Concomitantly,
inhibition of autophagy by 3-methyladenine treatment sen-
sitizes rats to the development of puromycin-aminonucleo-
side–induced FSGS, whereas rapamycin partially protects
podocytes from puromycin-aminonucleoside–induced
nephropathy.149
Autophagy in other nondiabetic glomerular diseases. A
limited amount of studies brought direct evidence for auto-
phagy in other models of glomerulopathies, principally
antibody-mediated glomerular diseases.
A major role for B-cell autophagy was shown in a mouse
model of lupus nephritis, the spontaneous mutant mouse
Y-linked autoimmune accelerator with duplication of the
Toll-like receptor 7 (Tlr7) gene. Autophagy in CD19þ cells
mediates Toll-like receptor 7–dependent autoimmunity and955
Table 3 | Effects of kidney cell–speciﬁc deletion of potential modulators of autophagy
Name Tissue
Cre-driven
expression Renal disease model Phenotype/renal phenotype Comments References
Nphs2-cre Tsc1ﬂ/ﬂ Podocytes Nphs2 None DN-like phenotype: glomerular
membrane thickening,
mesangial expansion, podocyte
loss, and proteinuria
No link with autophagy
established
72
Nphs2-cre Raptorﬂ/ﬂ Podocytes Nphs2 None Increased proteinuria by 4 wk of
age.
Podocyte degeneration and
progressive
glomerulosclerosis by 12 mo
No link with autophagy
established
71
Nphs2.rtTA;tetO Raptorﬂ/ﬂ Podocytes Nphs2 None Glomerular synechiae No link with autophagy
established
71
Nphs2-cre mTorﬂ/ﬂ Podocytes Nphs2 None Massive proteinuria by 4 wk
of age.
Podocyte degeneration and
early-onset glomerulosclerosis
mTOR inhibition
disrupts the
autophagic pathway in
podocytes
in vitro
128
Ksp-cre Raptorﬂ/ﬂ Distal tubule Ksp None Defective concentrating
mechanisms
and polyuria
No link with autophagy
established
Pax8.rtTA;tetO.Cre
Raptorﬂ/ﬂ
Proximal, distal,
and collecting
duct tubules
Pax8 IRI More severe cell sloughing, cell
ﬂattening,
and distal tubular cast formation
No link with autophagy
established
129
Nphs2-cre Sirt1ﬂ/ﬂ Podocytes Nphs2 db/db DN Increased urinary proteins No link with autophagy
established
130
Nphs2-cre Sirt1ﬂ/ﬂ Podocytes Nphs2 NTS-induced RPGN,
PS-induced podocyte
injury
Increased sensitivity to podocyte
injury
No link with autophagy
established
131
Sirt1Tg (Npt2) Proximal tubule Npt2 cisplatin-induced AKI Less oxidative stress and
decreased
cisplatin-induced renal injuries
No link with autophagy
established
89
db/db DN and 5/6
Nphx
Proximal tubule-speciﬁc Sirt1
overexpression alleviates
diabetic albuminuria in db/db
mice
but not in 5/6th nephrectomized
No link with autophagy
established
89
g-GT-cre Sirt1ﬂ/ﬂ Proximal tubule g-GT STZ-induced DN Increased sensitivity to DN No link with autophagy
established
90
AKI, acute kidney injury; DN, diabetic nephropathy; IRI, ischemia-reperfusion injury; Ksp, cadherin 16, KSP-cadherin gene; mTOR, mammalian target of rapamycin; Nphs2,
nephrosis 2, idiopathic, steroid-resistant (Podocin) gene; Nphx, nephrectomy; NTS, nephrotoxic serum; Pax8, paired box 8 gene; PS, protamine sulfate; RPGN, rapid and
progressive glomerulonephritis; Sirt1, sirtuin 1; STZ, streptozotocin; Tsc1, tuberous sclerosis 1 gene.
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transgenic (Tg) mice with B-cell–speciﬁc ablation of auto-
phagy (Cd19-Cre Atg5lox/lox) was markedly alleviated
compared with mice without B-cell–speciﬁc autophagy
deﬁciency.153
By contrast, the role of autophagy in other cell types is
protective in models of antibody-mediated nephritis, such as
lupus nephritis and nephrotoxic serum nephritis. Amino acid
metabolism triggers interferon-g–mediated induction of
indoleamine 2,3-dioxygenase 1 enzyme activity with subse-
quent activation of a stress response dependent on the
eIF2alpha kinase general control nonderepressible 2. Consis-
tent with a role in prevention of apoptotic cell driven
autoreactivity, myeloid deletion of general control non-
derepressible 2 in lupus-prone mice resulted in increased
immune cell activation, humoral autoimmunity, and renal
disease.154 Interestingly, the indoleamine 2,3-dioxygenase–
general control nonderepressible 2 pathway in podocytes and
other cells was suggested to be a critical negative feedback956cascade that limits inﬂammatory renal injuries by inducing
autophagy in a model of nephrotoxic serum nephritis.155
Increasing kidney indoleamine 2,3-dioxygenase 1 activity or
treating mice with a general control nonderepressible 2
agonist induced autophagy and protected mice from nephritic
kidney damage. Interestingly, kidneys from patients with
antibody-driven nephropathy showed increased indoleamine
2,3-dioxygenase 1 abundance and stress gene expression,
suggesting interplay between autophagy and interferon-
g–mediated protective feedback cascade.155
Autophagy in DN. DN is the leading cause of end-stage
renal disease in industrialized countries. Progressive loss of
podocytes and microvascular alterations appear to most
closely correlate with the functional renal decline in
DN.156–158 Progressive podocyte injury characterized by cell
detachment, hypertrophy, and foot process effacement plays a
central role in the development of DN in both type 1 and type
2 diabetes mellitus.132,158–160 Over the past decade, several
studies have provided indirect and direct evidence thatKidney International (2016) 90, 950–964
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First, autophagy can be induced by high glucose levels in
various cell types, partly through hyperglycemia-mediated
production of reactive oxygen species, and it has protective
effects in vitro.163–165
In podocytes, high glucose levels lead to podocyte
apoptosis in vitro that is mediated through caspase-3 activa-
tion.166 High glucose concentration also induces auto-
phagy.165,167,168 However, prolonged exposure to
hyperglycemia results in depressed podocyte autophagy.169
This secondary downregulation of autophagy may play a
role in disease progression and may be linked to podocyte
hypertrophy through the upregulation of the cyclin-
dependent kinase inhibitor p27/Kip1170 and activation of
mTOR.71,72 Furthermore, activation of mTOR was associated
with an accelerated glomerular injury in DN.71,152 Although
rapamycin, resveratrol, and caloric restriction treatments
affect many pathways besides the autophagy pathway, several
studies have shown that they have positive effects on
inﬂammation, tubular injury, glomerulosclerosis, and
podocyte injury in rodent models of DN.93,171–177 Taurine-
conjugated ursodeoxycholic acid also restores high-glucose–
suppressed autophagy and podocin expression in podocyte
culture, and it attenuates albuminuria in diabetic mice.168
Direct evidence for the protective role of autophagy during
DN is coming from recent work demonstrating that podocyte
Atg5 deﬁciency increased high-glucose–induced apoptosis.
Moreover, speciﬁc podocyte autophagy deﬁciency (in
Nphs2.Cre Atg5lox/lox mice) resulted in accelerated diabetes-
induced podocytopathy as shown in models of type I167 and
type II DN.178 Thus, chronic alteration of podocyte auto-
phagy may contribute to DN progression, and ﬂuctuations of
autophagy in the diabetic podocyte over time could be an
interesting paradigm for stage-speciﬁc interventions. Histone
deacetylase 4 may participate to suppression of podocyte
autophagy.179 Expression level of histone deacetylase 4 was
shown to negatively correlate with estimated glomerular
ﬁltration rate in individual patients with DN and was up-
regulated in kidney tissues of rats with streptozotocin-
induced diabetes as well as in diabetic db/db mice. A
pattern of histone deacetylase 4 expression was prominent in
cultured podocytes upon incubation with a high concentra-
tion of glucose and in podocytes from individuals with DN or
FSGS. Histone deacetylase 4 inhibition sustained the high
constitutive autophagy in podocytes.
Alteration of proteostasis and autophagy in the tubular
compartment also takes place in diabetic kidneys and in cells
exposed to a high concentration of glucose or advanced gly-
cation end products. An early work investigating the activity
of chaperone-mediated autophagy in rat kidney cortical ly-
sates upon induction of diabetes revealed that reduced
chaperone-mediated autophagy contributes to accumulation
of speciﬁc proteins in diabetic-induced renal hypertrophy.180
The implication of such changes in DN progression is un-
known. A recent work demonstrated that ubiquitinated pro-
tein bodies were delivered to the autophagy machinery butKidney International (2016) 90, 950–964not degraded by the impaired lysosomes of HK-2 cells
exposed to advanced glycation end product–bovine serum
albumin.181 Again, this study suggests that the autophagy-
lysosome pathway is disrupted by advanced glycation end
products in tubular epithelial cells during the development of
DN, which results in the accumulation of abnormal proteins.
Progressive and irreversible microvascular damage and loss
are also observed in the diabetic kidney, and a decrease in the
function and density of intrarenal microvessels has been re-
ported in several studies.182–185 Interestingly, the treatment of
diabetic mice with resveratrol, a well-known inducer of
autophagy, protects from intraglomerular capillary rarefac-
tion, suggesting that resveratrol attenuates DN by modulating
angiogenesis.186
Moreover, autophagy protects from high glucose–induced
senescence in cord human venous endothelial cells.187 Finally,
endothelial-speciﬁc deletion of Atg5 (Cdh5.Cre Atg5lox/lox
mice) leads to increased diabetes-induced renal endothelial
injury, as shown by interstitial and glomerular capillary rar-
efactions and glomerular endothelial cells’ loss of
fenestrations.167
Interestingly, epidermal growth factor receptor activation
detected in diabetic glomeruli was associated with ER stress,
decreased autophagy, and accelerated diabetic glomerulop-
athy.169 Therefore, pharmacologic epidermal growth factor
receptor kinase inhibition may have therapeutic implications
in DN.169
In summary, autophagy acts as a protective mechanism on
both cellular layers of the glomerular ﬁltration barrier in DN.
Autophagy in the tubulointerstitial compartment
Autophagy in AKI. Most cases of AKI are caused by renal
ischemia-reperfusion, sepsis, xenobiotic agents, drugs, and
metals, which are risk factors for development of chronic
kidney diseases.188,189 Autophagy is now generally accepted as
a renoprotective cellular response in AKI of various cau-
ses.36,190–203 An in-depth review of the relationship between
autophagy and AKI has been published in this journal.204
Autophagy in renal ﬁbrosis. Unilateral ureteral obstruction
(UUO) in rodents has been established as a classic model of
progressive renal ﬁbrosis.205 Autophagy markers were
increased in obstructed renal tubules in a UUO model.
Indeed, BECN1 and LC3-II are overexpressed during the time
course of renal injury and accompany tubular atrophy and
tubular cell death.77,206,207 Nevertheless, the positive or
negative impact of autophagy induction in UUO is not clear.
The autophagy inhibitor 3-methyladenine enhances tubular
cell apoptosis and tubulointerstitial ﬁbrosis in the obstructed
kidney in rats after ureter obstruction, suggesting that auto-
phagy induced by UUO has a renoprotective role in the
obstructed kidney.77 The protective function of autophagy in
tubules during ureteral obstruction was also demonstrated
recently by the use of genetically modiﬁed animals deﬁcient
for the autophagy pathway.207 In renal tubular epithelial cells,
autophagy regulates expression of transforming growth factor
beta (TGF-b) by promoting autophagic degradation of957
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haploinsufﬁciency (in Bcn1þ/- mice) resulted in increased
levels of mature TGFbeta and was associated with more severe
ﬁbrosis and renal tubular epithelial cell apoptosis in the
obstructed kidney after UUO. Interestingly, TGF-b itself
stimulates autophagy.207 On the other hand, it was found that
under the stimulus of persistent UUO, the induction of
autophagy in the proximal tubules contributes to cell death.
Indeed, the authors found that mitochondrial structure
changes during UUO and lipid peroxidation product, reduced
nicotinamide adenine dinucleotide phosphate oxidase 4, and
reduced nicotinamide adenine dinucleotide phosphate oxi-
dase activity are increased in the obstructed renal cortex,
whereas mitochondrial injury leads to autophagy and
apoptosis through the BECN1 pathway and Bcl2 interaction.
Therefore, during UUO, oxidative stress that leads to mito-
chondrial damage could drive autophagy-dependent cell
death and apoptosis and could be a mechanism of tubular
atrophy.208
The sequestration of damaged lysosomes by autophagy is
another emerging role for autophagy in epithelial mainte-
nance. This involves complex process of selective lysosome
recognition, engulfment, and degradation or so-called
lysophagy.209 This proved to be the case in tubular kidney
cells, in which under conditions of lysosomal damage, loss of
autophagy caused inhibition of lysosomal biogenesis in vitro
and deterioration of AKI in vivo.210
LC3-associated phagocytosis in tubular cells. Although
several studies suggested that cells from proximal tubules play a
signiﬁcant role in removing apoptotic cells and debris via
phagocytosis or heterophagy, recent evidence suggests that
proximal tubular cells also exert noncanonical autophagy in
cell corpse clearance, termed LC3-associated phagocytosis. In
this clearance pathway, LC3 is targeted to the phagosome in an
ATG5-, ATG7-, and BECN1-dependent manner; however, this
process does not classically involve the engagement of upstream
autophagy proteins such as ULK1.211–213 A recent study found
that kidney injury molecule-1 (KIM-1)/T-cell Ig and mucin
domain 1, a phosphatidylserine phagocytosis and scavenger
receptor expressed by kidney proximal tubule epithelial cells, is
the dominant apoptotic cell phagocytosis receptor in these
cells.214 Originally, upon ligand extracellular recognition,
binding and phosphorylation of KIM-1 cytosolic domain
interacted with the phosphoinositide 3–kinase pathway and
stimulated LC3 lipidation and autophagy induction with pro-
gressive appearance of KIM-1-and LC3-positive organelles
characteristic of autophagy. Unlike standard LC3-associated
phagocytosis described in professional phagocytic cells, KIM-
1 expression induced phosphorylation and activation of
ULK1/ATG1, which is essential for autophagosome formation.
These results also suggest that KIM-1 phagosomes are degraded
by autophagy. In summary, this cascade described in kidney
proximal epithelial cells represents a novel mechanism by
which autophagosomes generated in an ULK1-dependent
manner target phagosomes for degradation, which has po-
tential pathophysiological implications as kidney injury inmice958carrying a nonfunctional mutant KIM-1 results in a worsening
of AKI with the accumulation of unphagocytosed apoptotic
cells and increased inﬂammation.214,215 Beyond the case of
AKI, we hypothesize that interplay between KIM-1–mediated
phagocytosis, tubular autophagy, and inﬂammationmay play a
role in resolution of inﬂammation, scarring processes, and
progression of chronic nephropathies.
Autophagy and metabolic acidosis. Metabolic acidosis in-
duces autophagy in proximal tubular cells in vitro and in vivo.
Kidneys of acid-loaded proximal tubule–speciﬁc autophagy-
deﬁcient mice (Atg5lox/lox:KAP-Cre mice) exhibited an
increased number of SQSTM1/p62 and UB-positive aggre-
gates in the kidney proximal tubular cells compared with in
the vehicle-treated Atg5lox/lox:KAP-Cre mice. Furthermore,
acid-loaded Atg5lox/lox:KAP-Cre mice showed signiﬁcantly
more severe acidosis than did the acid-loaded controls, with
impaired ammoniagenesis indicating a protective role for
ATG5 on ammoniagenesis. This was linked to deﬁciency in
proper mitochondrial functions, including ammoniagenesis
in Atg5lox/lox:KAP-Cre animals, as basal mitochondrial oxygen
consumption rate, the adenosine triphosphate–linked oxygen
consumption rate, and maximum respiratory function were
signiﬁcantly more reduced by acid loading in ATG5-deﬁcient
proximal tubular cells than in ATG5-competent proximal
tubular cells.216
Autophagy PKDs. Several pieces of evidence suggest that
autophagy could play roles in PKDs in cyst formation and
growth. Indeed, electron microscopy, immunoﬂuorescence,
and immunoblot demonstrated LC3-II and BECN1 over-
expression and increased number of autophagosomes in
polycystic kidneys, thus suggesting autophagic ﬂux dysregu-
lation in PKD.217 Moreover, PKD is a cilia-related disease and
autophagy was recently shown to be implicated in cilio-
genesis,218 whereas primary cilia are required for the activa-
tion of autophagy.219 Therefore, the close relationship
between ciliogenesis and autophagy constitutes an exciting
method of investigation in the ﬁeld of cilia-related disease
such as PKD. Finally, autophagy modulators have been
implicated in PKD progression. The PtdIns3K–v-akt murine
thymoma viral oncogene homolog 1–tuberous sclerosis
complex–mTOR pathway is activated in PKD, and rapamycin
has shown proof of therapeutic effects on animal models of
PKD220–226 but not in patients.227,228 Interestingly, a low dose
of rapamycin results in protection from PKD without effects
on apoptosis,225 whereas a higher dose of rapamycin increases
apoptosis of cyst-lining epithelial cells in PKD.226 Moreover, it
was shown recently that metformin, a known AMPK inducer,
slows cyst formation.229 Even if the authors did not establish
any link between AMPK activation and autophagy induction,
this study suggests that autophagy induction, mediated by
metformin, could be renoprotective in PKD. Further studies
on the link between autophagy and cyst formation in PKD are
required to clarify the functions of autophagy.
Autophagy and aging. The renal tubulointerstitial com-
partment is not spared from aging-induced damage. Tubular
atrophy, apoptosis, and ﬁbrosis are associated with a declineKidney International (2016) 90, 950–964
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evidence suggests that autophagy is protective in proximal
tubules cells during aging. Indeed, mice with a speciﬁc
autophagy deﬁciency in renal proximal tubular cells
(Atg5lox/lox;KSP.Cre and Atg5lox/lox; Pax8.rtTA;TetO.Cre mice)
have increased accumulation of damaged mitochondria,
ubiquitinated proteins, and SQSTM1-positive aggregates,
which are associated with tubular apoptosis and tubu-
lointerstitial ﬁbrosis.192,230 These studies showed that auto-
phagy deﬁciency in renal tubular cells leads to premature
aging. Consequently, autophagy activation in the aging kidney
would prevent tubular lesions development and protect from
age-related renal dysfunction. Calorie restriction is a major
inducer of autophagy and has been correlated with increased
life span in eukaryotes.231,232 Interestingly, calorie restriction
protects from age-related kidney damage233,234 and autophagy
underlies calorie restriction–mediated renal protection.233 It
was recently demonstrated that SIRT1 mediates forkhead box
O3 deacetylation in response to calorie restriction and leads
to restoration of autophagy in aged kidneys.233,235 Resveratrol
is an antioxidant that occurs naturally in many plant parts
and products, such as grapes, berries, red wine, and peanut
skins. Resveratrol activates SIRT1, and previous reports have
shown that resveratrol can ameliorate several types of renal
injury, such as DN, ischemia-reperfusion injury, and UUO
among others, in animal models through its antioxidant effect
or SIRT1 activation. Therefore, resveratrol may be a prom-
ising treatment for preventing age-related renal injury.236
PUTATIVE THERAPEUTIC TARGETS AND CLINICAL
IMPLICATIONS
Inducing autophagy could be a promising therapeutic strategy
for the treatment of renal diseases. Nevertheless, all the
cytoprotective effects of autophagy were found in rodent
models of renal diseases, and so far, proof is lacking that these
ﬁndings can be transferred to human diseases. To date, the
only autophagy inducers commonly used in human medicine
are mTOR inhibitors (sirolimus and everolimus), which are
widely used as immunosuppressive agents. However, it is now
well established that in humans these antiproliferative mTOR
inhibitors have adverse effects on compensatory renal
epithelial cell hypertrophy and recovery from ischemia
following renal transplantation.237–239 Moreover, sirolimus is
associated with numerous side effects, including diabetes
mellitus, systemic inﬂammation, or edema among others.237
Thus, the use of mTOR inhibitors as autophagy inducers
appears to not be a feasible strategy in many cases. Resveratrol
supplementation is currently being tested in several clinical
trials, essentially for safety of use, for weight loss therapy, and
in elderly individuals, and it seems to be safe at the doses
tested.240–243
In summary, to date there is a lack of reliable biomarkers
and clear interventional strategies targeting autophagy in
renal diseases. Thus, a speciﬁc approach that enables
pathway-speciﬁc and kidney-selective regulation of autophagy
would be required. Recently, a Tat-Beclin fusion protein hasKidney International (2016) 90, 950–964been found to selectively induce autophagy without side ef-
fects on other signaling pathways, offering novel perspectives
for potential treatment strategies.244
CONCLUSION
Because autophagy is a dynamic process, instant pictures
from cells or tissues cannot bring robust information
regarding induction or inhibition of this homeostatic phe-
nomenon. Therefore, information gained from animal
models has been precious. The development of a conditional
knockout mice enabling targeting of autophagy in rodent
models of renal diseases has signiﬁcantly deepened our
knowledge of the role of autophagy in these conditions. Most
of the direct studies of autophagy systems in vivo have used
loss-of-function approaches rather than speciﬁc gain-of-
function approaches, which may be seen as a limitation.
Meanwhile, most of these studies are in accord regarding a
protective function of autophagy in the kidney, highlighting
autophagy as a novel and very promising target for renal
diseases therapy. However, further studies are required to
elucidate the precise and cell-speciﬁc programs regulating
autophagy in renal diseases. There is also a pressing need for
robust biomarkers that accurately assess the clinical utility of
modulating autophagy in various disease contexts. In-
vestigations of kidney disease–dependent triggers, sensors,
and adaptors that tailor the autophagy machinery might drive
biomarker discovery to achieve target speciﬁcity. Moreover,
selective autophagy modulators and (cell-)speciﬁc delivery
routes remain to be elucidated to ultimately hopefully offer
novel treatment options for our kidney patients.
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